Amneal Scores Second US Biosimilar Approval With Avastin Rival
Alymsys Bevacizumab With mAbxience Is Second Of Three Expected Nods This Year
Amneal has received approval for its second US biosimilar in the form of the mAbxience-developed Alymsys rival to Avastin. The product represents just the third biosimilar version of bevacizumab to be approved in the US.
You may also be interested in...
Amneal says it has “officially entered the US biosimilar market” after introducing its Alymsys biosimilar bevacizumab rival to Avastin. The biosimilar launch represents the first of three expected for Amneal in 2022, following US FDA approvals earlier this year.
Pfizer has reported healthy growth of a tenth for its biosimilars portfolio in the first half of 2022, at the same time as its sterile injectables sales slipped by a similar degree.
Amneal has celebrated its third US biosimilar approval of 2022 with an FDA nod for its Fylnetra (pegfilgrastim-pbbk) rival to Neulasta, as the firm makes launch preparations for all three products across the second half of the year.